Related Experiment Video
Updated: Jul 7, 2026
06:29
Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells
Published on: July 30, 2020
Aurora B kinase expression in ependymal neoplasms
Sarah E Gibson1, Weifen F Zeng, Robert J Weil
1Department of Anatomic Pathology, Cleveland Clinic, Cleveland, OH 44195, USA.
Applied Immunohistochemistry & Molecular Morphology : AIMM
|February 28, 2008
Summary
Aurora B kinase overexpression is linked to higher-grade ependymomas, but unlike in astrocytomas, it does not correlate with patient outcomes. Further research into Aurora kinase inhibitors for ependymoma treatment is warranted.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Cell Cycle Regulation
Background:
- Aurora B kinase is crucial for cell division and its overexpression correlates with aggressive astrocytomas.
- Understanding Aurora B kinase expression in different ependymoma subtypes is important for potential therapeutic strategies.
Purpose of the Study:
- To investigate the expression levels of Aurora B kinase in various ependymoma subtypes.
- To determine the association between Aurora B kinase expression and tumor grade, and clinical outcomes in ependymomas.
Main Methods:
- Immunohistochemistry was used to evaluate Aurora B kinase expression.
- Analysis included 32 ependymomas, 10 anaplastic ependymomas, 16 myxopapillary ependymomas, and 9 subependymomas.
- Statistical analysis was performed to correlate Aurora B expression with tumor grade and clinical parameters.
Main Results:
- Aurora B expression was detected in 62.5% of ependymomas, 50% of anaplastic ependymomas, and 6.3% of myxopapillary ependymomas; none in subependymomas.
- A significant association was found between Aurora B expression and World Health Organization grade II/III tumors (P<0.0001).
- No correlation was observed between Aurora B expression and patient age, sex, tumor location, recurrence, or mortality.
Conclusions:
- Elevated Aurora B kinase expression is associated with higher-grade ependymomas.
- Unlike in astrocytomas, Aurora B expression in ependymomas does not correlate with clinical course or patient survival.
- Aurora B kinase may represent a potential therapeutic target for ependymoma treatment, warranting further investigation into Aurora kinase inhibitors.
